Vitamin K2 MK-7 (Menaquinone-7) 90 mcg
Goals
$19.13 $0.31 per serving
Product analysis
Vitamin K2 MK-7 (Menaquinone-7) 90 mcg offers economical, targeted support for vitamin K needs involved in bone mineral handling.
AI assessment of the formula, label and price. How scoring works
Nutrient Quality100
MK-7 is a favorable, clearly identified vitamin K form. The single source makes the preparation straightforward to compare.
Ingredient Transparency100
The active vitamin K amount and MK-7 form are clearly disclosed. You can compare the serving directly with other vitamin K supplements.
Value For Money100
The MK-7 serving offers favorable value. Its simple formula makes the cost comparison straightforward.
Customer Satisfaction80
Customer feedback is very positive. The smaller review base makes the satisfaction picture less established than a heavily reviewed option.
Product Focus69
The formula targets vitamin K needs, with limited findings for bone density and selected blood-vessel stiffness measures. The 90 mcg serving is below a favorable long-term trial’s daily amount, so the same result cannot be assumed.
- Format
Softgel - Container
- 60 Softgel(s)
- Per serving
- $0.31
- Also available
Vitamin K2 MK-7 (Menaquinone-7) 45 mcg$33.92- Customer rating
- 4.8 · 567 ratings
Goals
Impact
High effect
Vitamin K · 90 mcg
MK-7 supports activation of proteins involved in bone mineral handling. MenaQ7 identifies the MK-7 form, and this serving declares 90 mcg of active vitamin K. Limited trials in postmenopausal women have mixed bone-density findings, with one favorable trial using 180 mcg daily for three years. This smaller serving cannot be assumed to reproduce that result, and general fracture prevention is not established.
How this product is rated for Bone Health
Ingredient fit76
The single declared MK-7 ingredient gives the product a focused bone-protein role.
Goal fit
The product focuses on MK-7, with no unrelated actives diluting its relevant ingredient contribution.
Dose adequacy
The 90 mcg serving is below the 180 mcg daily exposure in the favorable long-term trial.
Pathways40
Bone-protein activation is its sole substantially represented function.
Depth
MK-7 supplies the bone-protein activation contribution.
Breadth
Only bone-protein activation is substantially represented; mineral supply and calcium absorption are not covered.
Evidence98
The relevant evidence concerns MK-7 in postmenopausal women, with mixed bone-density findings.
Evidence strength
MK-7 provides the relevant but limited and mixed bone-density evidence.
Studied preparation
MenaQ7 establishes MK-7 identity; it does not imply a branded efficacy advantage.
Formulation logic100
The MK-7 serving is recognized without an unmet partner requirement or configured conflict.
Partner coverage
MK-7 has no unmet partner requirement in the supplied findings.
Conflicts
No configured conflict was identified; the high-vitamin-D condition is inapplicable because vitamin D is absent.
Effective doses
The MK-7 serving meets the amount threshold used for inclusion.
Impact
High effect
Vitamin K · 90 mcg
MenaQ7 vitamin K2 supplies MK-7, which has limited evidence for improving selected measures of arterial stiffness, mainly in postmenopausal women with greater starting stiffness. The 90 mcg serving is below the 180 mcg daily exposure used in the longer trial. These findings do not establish prevention of heart attacks or a general advantage for all vitamin K2 products.
How this product is rated for Heart Health
Ingredient fit72
MK-7 provides the product's focused connection to heart health. The declared MK-7 amount makes a partial contribution relative to the comparison amounts.
Goal fit
MK-7 provides the product's focused connection to heart health.
Dose adequacy
The declared MK-7 amount makes a partial contribution relative to the comparison amounts.
Pathways16
MK-7 supplies partial support within the arterial stiffness category.
Depth
MK-7 supplies partial support within the arterial stiffness category.
Breadth
The contribution stays below the broader coverage threshold, with no additional covered category.
Evidence77
MK-7 has limited arterial-stiffness evidence in selected populations.
Evidence strength
MK-7 has limited arterial-stiffness evidence in selected populations.
Studied preparation
The declared MK-7 preparation is recognized in the saved findings.
Formulation logic100
The ingredient works without a required missing partner. No listed ingredient conflict was triggered by the supplied facts.
Partner coverage
Every included ingredient can contribute without a required missing partner.
Conflicts
No listed ingredient conflict was triggered by the supplied facts.
Effective doses
1 included ingredient meets the saved minimum amount criterion; this is not proof of clinical effectiveness.
Impact
Moderate effect
Vitamin K · 90 mcg
Vitamin K2 MK-7 provides 90 mcg per serving of the specifically identified menaquinone form. It maps to partial arterial-stiffness marker coverage, but no target pathway reaches the broader coverage level. The relevant research concerns selected stiffness measures, not proof of fewer cardiovascular events.
How this product is rated for Cardiovascular Support
Ingredient fit72
The single active is the reviewed MK-7 form, with no off-goal ingredients.
Goal fit
MK-7 is tightly focused on a cardiovascular marker, though the product is linked to three goals.
Dose adequacy
The 90 mcg serving provides partial MK-7 exposure, below the 180 mcg daily study amount.
Pathways16
MK-7 relates only to arterial stiffness; no other cardiovascular pathway is represented.
Depth
Arterial-calcification control is the only represented pathway, with partial coverage.
Breadth
No target pathway reaches the breadth level.
Evidence69
MK-7 has limited marker evidence for this goal and is the only active ingredient.
Evidence strength
The evidence ceiling is modest compared with the strongest available for this goal.
Studied preparation
The identified MK-7 form is represented in a studied preparation.
Formulation logic100
The single active works independently, and no conflict is identified.
Partner coverage
MK-7 has a standalone role for the marker pathway described.
Conflicts
No conflict is identified in the available ingredient record.
Effective doses
The 90 mcg amount reaches the lower contribution range but remains below the study amount.
Ingredients
| Ingredient | Amount per serving | Score |
|---|---|---|
Vitamin K2 (Menaquinone-7) | 90 mcg |
Vitamin K (Menaquinone-7) · 90 mcg OverallScore93
Each serving provides 90 mcg of vitamin K2 as MK-7, a favorable amount in the evaluation. The whole-product serving costs about $0.32.
How this ingredient is rated
Active Ingredient Quality & Bioavailability82
MK-7 is the identified vitamin K form. The saved information does not specify whether it is the trans isomer.
Vitamin K Form (MK-7 vs. MK-4 vs. K1)
Vitamin K is present as K2 in the MK-7 form.
MK-7 Isomer Disclosure
The saved information identifies MK-7 but does not specify a trans isomer.
Dose, Safety & Label Transparency100
The serving provides 90 mcg of MK-7, a favorable amount in the evaluation; the amount and form are identified.
Vitamin K2 (MK-7) Dosage Efficacy
Each serving provides 90 mcg of MK-7, a favorable amount in the evaluation.
Form and Subtype Transparency
The saved facts identify both the MK-7 form and its 90 mcg amount per serving.
Value100
The whole-product serving costs about $0.32, a low price in this evaluation.
Price per Effective MK-7 Serving
The whole-product serving costs about $0.32, a low price in this evaluation.
Alternative products
Report alternatives
Sources
Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.
- Vitamin K and the prevention of fractures: systematic review and meta-analysis of randomized controlled trials.
- Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women.
- Effect of combined administration of vitamin D3 and vitamin K2 on bone mineral density of the lumbar spine in postmenopausal women with osteoporosis.
- Efficacy and safety of vitamin K2 for postmenopausal women with osteoporosis at a long-term follow-up: meta-analysis and systematic review.
- Low-dose vitamin K2 (MK-4) supplementation for 12 months improves bone metabolism and prevents forearm bone loss in postmenopausal Japanese women.
- Vitamin K Intake and Atherosclerotic Cardiovascular Disease in the Danish Diet Cancer and Health Study.
- Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women. A double-blind randomised clinical trial.
- Effects of One-Year Menaquinone-7 Supplementation on Vascular Stiffness and Blood Pressure in Post-Menopausal Women.
- Dietary Vitamin K1 Intake and Incident Aortic Valve Stenosis.
- Association between vitamin K1 intake and mortality in the Danish Diet, Cancer, and Health cohort.
- The effect of vitamin K1 on arterial calcification activity in subjects with diabetes mellitus: a post hoc analysis of a double-blind, randomized, placebo-controlled trial.